Compare Quest Diagnostics Inc (DGX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Banco Santander SA — how do they compare? Quest Diagnostics Inc trades at $230.94 (market cap $25.48B), while Banco Santander SA trades at $13.44 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 7.6× Quest Diagnostics Inc's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Banco Santander SA for 55 Days on average.
| DGX | SAN | |
|---|---|---|
Market Cap | $25.48B | $192.86B |
Volume | 941,866 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $247.45 | $15.05 |
52-Week Low | $173.49 | $9.65 |
Typical Hold Time | 56 Days | 55 Days |
Enterprise Value | $31.23B | $360.86B |
Dividend Yield | 1.49% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
